Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE1625 for cognitive impairment in schizophrenia
NCT00439634Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of OPNT004 in schizophrenia, sponsored by Sanofi. Started Feb 2007; status: terminated.
02
Drugs
OPNT004
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00439634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439634.